Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells

BACKGROUND: The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in diabetics undergoing percutaneous coronary intervention. These β(3 )integrin inhibitors antagonize fibrinogen binding to α(IIb)β(3 )integrins on platelets and ligand binding to α(v)β(3 )integrins on vascular ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Pathak, Alokkumar, Zhao, Renyi, Huang, Jianhua, Stouffer, George A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628888/
https://www.ncbi.nlm.nih.gov/pubmed/19108709
http://dx.doi.org/10.1186/1475-2840-7-36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628888/
https://www.ncbi.nlm.nih.gov/pubmed/19108709
http://dx.doi.org/10.1186/1475-2840-7-36

Ejemplares similares